Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney function affects how drug for diabetes and weight loss works

NCT ID NCT06929156

Knowledge-focused Sponsor: BrightGene Bio-Medical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how quickly the drug BGM0504 enters the blood and how long it stays in the body. Researchers compared 34 people with normal kidney function to those with mild or moderate kidney problems. The goal is to understand if kidney function changes how the drug should be dosed for treating type 2 diabetes and obesity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

34 people

The number who actually took part.

Started

May 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * √ Age 18-65 years on the date of signing informed consent (inclusive); * Body mass index (BMI) within the range of 19.0-30.0 kg/m2 (inclusive);. * Stable renal function, assessed by two eGFR during screening (apart at least 3 days); * Diagnosed as stable, chronic renal disease for at least 3 months. * Renal function, assessed by estimated glomerular filtration rate at screening (eGFR): 1. Normal renal function: 90-129 mL/min (inclusive); 2. Mild impairment: 60-89 mL/min (inclusive); 3. Moderate impairment: 30-59 mL/min (inclusive); 4. Severe impairment: 15-29 mL/min (inclusive); Exclusion Criteria: * ● Allergic constitution includes severe drug allergy or history of drug allergy; * Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2; Have a history or presence of pancreatitis; * Participants in clinical trials of any drug or medical device in the 3 months prior to screening;. * Suspected or confirmed history of alcohol or drug abuse; * Hepatitis B surface antigen (HBsAg), HIV antibody detection, hepatitis C virus antibody (HCVAb), treponema pallidum specific antibody detection, positive; * Donation or loss of 200 mL or more of blood within 3 months prior to screening, or blood donation during screening or within 1 months after the end of the trial; * Pregnant or Breast-feeding women; * The investigator considers that the participant has any other factors that would make it inappropriate to participate in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overweight or obese are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overweight or obese Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital, Shandong Province)

    Jinan, Shandong, 650100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.